Catalyst Pharmaceuticals reports Q1 2026 results today, May 12, having just posted its sharpest rally in months — with two sell-side downgrades arriving at the door.
The stock gained 25% over the past month and 7.6% in the past week alone, closing at $31.15. That rally has effectively priced in a lot of good news. It has also prompted two immediate pushbacks from the Street. Citigroup downgraded to Neutral from Buy on May 8, trimming its target from $35 to $31.50 — almost exactly where the stock now trades. Stephens & Co. simultaneously stepped down to Equal-Weight from Overweight. With six analysts covering the name, the consensus is now a Hold, and the mean target of $33.30 implies only about 7% upside. The message from the sell side is clear: the easy money on the re-rating may already have been made.
Short sellers are not pressing the bear thesis aggressively. Short interest has fallen roughly 17% over the past month to 6.5% of the free float — around 8 million shares. The borrow market is fully relaxed: cost to borrow runs at just 0.40%, and availability remains wide. The ORTEX short score has drifted down from the mid-50s to 47 over the past week, consistent with shorts reducing pressure into the print rather than adding to it. The setup here is less a short-squeeze tension and more a case of sellers quietly stepping aside as the stock appreciated.
Options positioning reinforces the bullish tone. The put/call ratio has dropped to 0.36, well below its 20-day average of 0.50 — nearly one standard deviation on the call-heavy side. That tilt toward calls has been building steadily since mid-April, coinciding almost exactly with the rally off the lows. RSI also reads at 73, technically extended territory. The shift in options positioning from predominantly bearish (the PCR was above 0.80 through early April) to clearly call-heavy today tracks the price move almost tick for tick, raising the question of whether the options market is chasing momentum rather than pricing new fundamental conviction.
The fundamental debate centers on growth durability. Bulls point to FIRDAPSE's expanding commercial footprint into the cancer-associated LEMS market and early traction from AGAMREE in Duchenne Muscular Dystrophy — a rare-disease franchise that management has argued can sustain double-digit revenue growth. Q1 consensus expects roughly $148 million in revenue with EPS near $0.64. The bear case centres on patent risk across the drug portfolio and the company's reliance on third-party manufacturing, which leaves revenue exposed to disruption at any of its three marketed products. The EV/EBITDA multiple near 9x is modest for a specialty pharma name but reflects the concentration risk embedded in a three-product orphan-disease franchise.
Today's print tests whether FIRDAPSE's growth rate and AGAMREE's commercial ramp can hold up against a stock that has repriced 33% year-to-date — and whether that is enough to reverse a Street that just moved to the sidelines.
See the live data behind this article on ORTEX.
Open CPRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
